A drug repurposing study identifies novel FOXM1 inhibitors with in vitro activity against breast cancer cells.

ABSTRACT: FOXM1, a proto-oncogenic transcription factor, plays a critical role in cancer development and treatment resistance in cancers, particularly in breast cancer. Thus, this study aimed to identify potential FOXM1 inhibitors through computational screening of drug databases, followed by in vitro validation of their inhibitory activity against breast cancer cells. In silico studies involved pharmacophore modeling using the FOXM1 inhibitor, FDI-6, followed by virtual screening of DrugBank and Selleckchem databases. The selected drugs were prepared for molecular docking, and the crystal structure of FOXM1 was pre-processed for docking simulations. In vitro studies included MTT assays to assess cytotoxicity, and Western blot analysis to evaluate protein expression levels. Our study identified Pant

SUBMITTER: Abusharkh KAN 

PROVIDER: S-EPMC11199234 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature